CA2816416C - Procedes et compositions pour le traitement de la diarrhee associee au hiv - Google Patents

Procedes et compositions pour le traitement de la diarrhee associee au hiv Download PDF

Info

Publication number
CA2816416C
CA2816416C CA2816416A CA2816416A CA2816416C CA 2816416 C CA2816416 C CA 2816416C CA 2816416 A CA2816416 A CA 2816416A CA 2816416 A CA2816416 A CA 2816416A CA 2816416 C CA2816416 C CA 2816416C
Authority
CA
Canada
Prior art keywords
crofelemer
per day
placebo
day
diarrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2816416A
Other languages
English (en)
Other versions
CA2816416A1 (fr
Inventor
William Forbes
Enoch Bortey
Steven King
Pravin Chaturvedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Napo Pharmaceuticals Inc
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2816416(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of CA2816416A1 publication Critical patent/CA2816416A1/fr
Application granted granted Critical
Publication of CA2816416C publication Critical patent/CA2816416C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des procédés pour le traitement de la diarrhée par administration à un patient ayant besoin d'un tel traitement, d'un inhibiteur du transport d'ions chlorure dans une quantité suffisante pour le traitement de la diarrhée. Le traitement de la diarrhée comporte le traitement de la diarrhée ainsi que le traitement de la douleur, de la gêne abdominale et d'autres symptômes associés à la diarrhée. Dans un mode de réalisation, l'inhibiteur du transport d'ions chlorure est le crofelemer.
CA2816416A 2010-10-31 2011-10-31 Procedes et compositions pour le traitement de la diarrhee associee au hiv Active CA2816416C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US61/408,622 2010-10-31
US40933510P 2010-11-02 2010-11-02
US61/409,335 2010-11-02
US41624910P 2010-11-22 2010-11-22
US61/416,249 2010-11-22
US201161434379P 2011-01-19 2011-01-19
US61/434,379 2011-01-19
PCT/US2011/058549 WO2012058664A1 (fr) 2010-10-31 2011-10-31 Procédés et compositions pour le traitement de la diarrhée associée au hiv

Publications (2)

Publication Number Publication Date
CA2816416A1 CA2816416A1 (fr) 2012-05-03
CA2816416C true CA2816416C (fr) 2020-02-11

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816416A Active CA2816416C (fr) 2010-10-31 2011-10-31 Procedes et compositions pour le traitement de la diarrhee associee au hiv

Country Status (19)

Country Link
US (4) US8962680B2 (fr)
EP (1) EP2632550B1 (fr)
JP (2) JP6063385B2 (fr)
CN (2) CN103370101A (fr)
AU (1) AU2011320155B2 (fr)
BR (1) BR112013010774A2 (fr)
CA (1) CA2816416C (fr)
DK (1) DK2632550T3 (fr)
EC (1) ECSP13012650A (fr)
ES (1) ES2635435T3 (fr)
HK (1) HK1249036A1 (fr)
HU (1) HUE035393T2 (fr)
MX (1) MX348184B (fr)
PE (1) PE20140036A1 (fr)
PL (1) PL2632550T3 (fr)
PT (1) PT2632550T (fr)
RU (1) RU2597746C2 (fr)
WO (1) WO2012058664A1 (fr)
ZA (1) ZA201303136B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
EP2015639A4 (fr) 2006-05-01 2009-11-25 Napo Pharmaceuticals Inc Méthode de traitement du syndrome du côlon irritable à constipation prédominante
AU2007248183B2 (en) 2006-05-01 2013-08-01 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
JP6063385B2 (ja) 2010-10-31 2017-01-18 ナポ ファーマシューティカルズ インコーポレイテッド Ｈｉｖ関連の下痢を治療するための方法および組成物
WO2014088629A1 (fr) * 2012-12-07 2014-06-12 Salix Pharmaceuticals, Ltd Procédés et compositions pour le traitement de la diarrhée associée au vih
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
JOP20220339A1 (ar) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائي
WO2022115481A1 (fr) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux d'une infection post-aiguë

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
DE69739394D1 (de) 1996-10-16 2009-06-18 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
WO2000047062A2 (fr) 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Formulations entero-solubles de supplements a base de polymeres de proanthocyanidine et procedes associes
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
WO2005074575A2 (fr) * 2004-01-30 2005-08-18 Microbia, Inc. Procedes et compositions pour traiter des troubles gastro-intestinaux
JP2008546790A (ja) * 2005-06-22 2008-12-25 ユニバーシティー オブ マサチューセッツ Ｈｉｖ−１プロテアーゼ阻害剤
WO2007068383A1 (fr) 2005-12-15 2007-06-21 Bayer Healthcare Ag Urees de diaryle pour le traitement d'infections virales
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
AU2007248183B2 (en) * 2006-05-01 2013-08-01 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
EP2015639A4 (fr) 2006-05-01 2009-11-25 Napo Pharmaceuticals Inc Méthode de traitement du syndrome du côlon irritable à constipation prédominante
WO2010021681A2 (fr) 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions et procédés pour le traitement de maladies virales
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011024049A2 (fr) 2009-08-26 2011-03-03 Glenmark Pharmaceuticals Ltd Procédé pour produire des compositions polymères proanthocyanidines pour des préparations pharmaceutiques
JP2013506716A (ja) * 2009-10-06 2013-02-28 ザ レゲンツ オブ ジ ユニヴァーシティ オブ カリフォルニア クロフェレマーなどのプロアントシアニジンオリゴマーを用いて疾患を治療する方法
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
JP6063385B2 (ja) 2010-10-31 2017-01-18 ナポ ファーマシューティカルズ インコーポレイテッド Ｈｉｖ関連の下痢を治療するための方法および組成物
RU2593014C2 (ru) 2011-01-27 2016-07-27 Гленмарк Фармасьютикалс Лимитед Способ производства проантоцианидиновой полимерной композиции
WO2013093655A1 (fr) 2011-12-22 2013-06-27 Glenmark Pharmaceuticals Limited Composition pharmaceutique non entérique comprenant du crofelemer
WO2014088629A1 (fr) 2012-12-07 2014-06-12 Salix Pharmaceuticals, Ltd Procédés et compositions pour le traitement de la diarrhée associée au vih

Also Published As

Publication number Publication date
US8962680B2 (en) 2015-02-24
EP2632550B1 (fr) 2017-05-03
PT2632550T (pt) 2017-08-02
ES2635435T3 (es) 2017-10-03
AU2011320155A1 (en) 2013-05-09
BR112013010774A2 (pt) 2017-03-21
CN103370101A (zh) 2013-10-23
JP2017019806A (ja) 2017-01-26
JP6310971B2 (ja) 2018-04-11
US9585868B2 (en) 2017-03-07
US20140294903A1 (en) 2014-10-02
HK1249036A1 (zh) 2018-10-26
MX348184B (es) 2017-06-02
ECSP13012650A (es) 2013-10-31
MX2013004873A (es) 2013-08-21
HUE035393T2 (en) 2018-05-02
US20120107370A1 (en) 2012-05-03
RU2597746C2 (ru) 2016-09-20
CA2816416A1 (fr) 2012-05-03
RU2013123794A (ru) 2014-12-10
PE20140036A1 (es) 2014-01-31
JP6063385B2 (ja) 2017-01-18
DK2632550T3 (en) 2017-08-07
AU2011320155B2 (en) 2016-02-25
EP2632550A4 (fr) 2014-04-23
CN107595836A (zh) 2018-01-19
EP2632550A1 (fr) 2013-09-04
ZA201303136B (en) 2016-01-27
WO2012058664A1 (fr) 2012-05-03
US20120184605A1 (en) 2012-07-19
US20150190367A1 (en) 2015-07-09
JP2013540826A (ja) 2013-11-07
PL2632550T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
CA2816416C (fr) Procedes et compositions pour le traitement de la diarrhee associee au hiv
US20140163096A1 (en) Methods and compositions for treating hiv-associated diarrhea
JP6159084B2 (ja) 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
de Freitas et al. Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against Candida spp. isolates and for vaginal candidiasis treatment
JP2020510675A (ja) ミトコンドリア起源のｒｏｓの産生の特異的阻害剤を使用した、薬物誘発ｑｔ間隔延長に関連するリスクの予防
US11779564B2 (en) Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
US11857510B2 (en) Methods and compositions for treating congenital diarrhea disorder
WO2022115481A1 (fr) Procédés et compositions pour le traitement de troubles gastro-intestinaux d'une infection post-aiguë
CN112789052A (zh) 用于保护皮肤免受紫外线辐射的番茄红素组合物和方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160907